Long-term Safety of Subjects Continuing Dolutegravir After Participation in Clinical Studies of Dolutegravir in Russian Federation

Trial Profile

Long-term Safety of Subjects Continuing Dolutegravir After Participation in Clinical Studies of Dolutegravir in Russian Federation

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 11 Jun 2018

At a glance

  • Drugs Dolutegravir (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors ViiV Healthcare
  • Most Recent Events

    • 05 Jun 2018 Planned End Date changed from 31 Jul 2018 to 14 Sep 2018.
    • 05 Jun 2018 Planned primary completion date changed from 31 Jul 2018 to 14 Sep 2018.
    • 01 Mar 2018 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top